![R. Mark Payne](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profilo
R.
Mark Payne is the founder of Chondrial Therapeutics, Inc. and held the titles of Director and Chief Scientific Officer.
Posizioni attive di R. Mark Payne
Società | Posizione | Inizio |
---|---|---|
Chondrial Therapeutics, Inc.
![]() Chondrial Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Chondrial Therapeutics, Inc. operates as a biotechnology company which focuses on the treatment of rare mitochondrial diseases. Its compound is CTI-1601, which the company is developing as a potential treatment for Friedreich’s Ataxia. The company was founded by Steven R. Plump and Mark R. Payne and is headquartered in Bala Cynwyd, PA. | Fondatore | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 1 |
---|---|
Chondrial Therapeutics, Inc.
![]() Chondrial Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Chondrial Therapeutics, Inc. operates as a biotechnology company which focuses on the treatment of rare mitochondrial diseases. Its compound is CTI-1601, which the company is developing as a potential treatment for Friedreich’s Ataxia. The company was founded by Steven R. Plump and Mark R. Payne and is headquartered in Bala Cynwyd, PA. | Health Technology |
- Borsa valori
- Insiders
- R. Mark Payne